As the leader in the field of medical innovation, China Medical Science and Medicine Institute has always insisted on creating new drugs with independent intellectual property rights. It is one of the national key drug research institutions.
In order to further improve the ability of the drug science and technology, according to the government procurement network information, in early August, the drug industry has invested heavily in improving the basic equipment for research. August 31, Institute of Materia Medica, Chinese Academy of Medical Sciences equipment The procurement project was successfully tendered for 62.756 million yuan.
It is reported that the huge procurement project is divided into five packages, including Baoyi and Baosan, and Baoji, Beijing, China, and China Resources Equipment, Zhongrun Huibao Technology, respectively, successfully won the bid. Each is 141.920 million yuan, 2511.55 million yuan, and 2344.89 million yuan. instrument Including online isotope detection tandem mass spectrometry system, gas chromatography-quadrupole time-of-flight mass spectrometer, nitrogen generator, inverted fluorescence microscope, triple quadrupole gas chromatography mass spectrometer, fully digital superconducting nuclear magnetic resonance spectrometer , laboratory type molecular distillation device, wide-angle dynamic and static laser light scattering instrument, micro sample distillation instrument and other large-scale analytical instruments and laboratory equipment.
section
Among them, Baoyi Beijing Boxinhua Technology and Beijing Bopute Technology have failed to meet the bidding requirements for scrapping. Baosan has less than three bids due to bidding companies. It is enough to see that in the instrument procurement market, enterprises often experience layer-by-layer battles. Only after the assessment took the big order. Obviously, this is inseparable from the product quality, brand influence and technology level of the three companies such as Chinese scientific equipment.
